GSE239844 crizotinib 8 v 12 human up (Gene Set)

Analyze

Playbook Workflow Builder
Playbook Workflow Builder: Gene Set Enrichment

Perform Gene Set Enrichment with this gene set against Common Fund program's gene sets, identifying significant overlaps using a pre-built PWB workflow. Run the workflow with GSE239844_crizotinib_8_v_12_human_up.

GeneSetCart
GeneSetCart

GeneSetCart helps you to fetch gene sets from various data sources, augment, combine with set operations, visualize and analyze these gene sets in a single session. Start a new session with GSE239844_crizotinib_8_v_12_human_up.

CFDE-GSE
CFDE Gene Set Enrichment (GSE)

CFDE-GSE illuminates connections between the input gene set and various CF gene sets that overlap with the queried gene set. Query CFDE-GSE with GSE239844_crizotinib_8_v_12_human_up.

Playbook Workflow Builder
Playbook Workflow Builder

The Playbook Workflow Builder helps you interactively construct workflows leveraging CFDE APIs without code. Start a new workflow with GSE239844_crizotinib_8_v_12_human_up.

Results found

Linked to

 

Label

Description

 

Gene

CD27 antisense RNA 1

Gene

long intergenic non-protein coding RNA 960

Gene

ANKRD13C divergent transcript

Gene

long intergenic non-protein coding RNA 2506

Gene

ETS repressor factor like

Gene

heterogeneous nuclear ribonucleoprotein A1 pseudogene 33

Gene

A1BG antisense RNA 1

Gene

ribosomal protein L23a pseudogene 21

Gene

PCDHB1 antisense RNA 1

Gene

NUTM2B antisense RNA 1

  • Gene

    CD27 antisense RNA 1


  • Gene

    long intergenic non-protein coding RNA 960


  • Gene

    ANKRD13C divergent transcript


  • Gene

    long intergenic non-protein coding RNA 2506


  • Gene

    ETS repressor factor like


  • Gene

    heterogeneous nuclear ribonucleoprotein A1 pseudogene 33


  • Gene

    A1BG antisense RNA 1


  • Gene

    ribosomal protein L23a pseudogene 21


  • Gene

    PCDHB1 antisense RNA 1


  • Gene

    NUTM2B antisense RNA 1

  • DISPLAY PER PAGE
    This repository is under review for potential modification in compliance with Administration directives.